medRxiv preprint doi: https://doi.org/10.1101/2024.02.03.24302058; this version posted February 6, 2024. The copyright holder for this preprint doi: https://doi.org/10.1101/2024.02.00.24 outhor/funder, who has granted medicary 0, 2024. The copyright holder for this perperint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

#### Pre-existing cancer cells and induced fibroblasts are key cells for early 1 chemoresistance in ovarian cancer 2

3

Langyu Gu<sup>1,#</sup>, Shasha He<sup>2,#</sup>, Linxiang Wu<sup>3,#</sup>, Yu Zeng<sup>4</sup>, Yang Zhang<sup>3</sup>, Chenqing 4 Zheng<sup>1</sup>, Chuling Wu<sup>3</sup>, Huishan Xu<sup>3</sup>, Xiaoyan Zhang<sup>3</sup>, Hongwei Shen<sup>3</sup>, Shuzhong 5 Yao<sup>3</sup>, Yufeng Ren<sup>2,\*</sup>, Guofen Yang<sup>3,\*</sup> 6

7

<sup>1</sup> State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-sen University, 8

- Guangzhou, 510275, Guangdong, China 9
- <sup>2</sup> Department of Radiation Oncology, the First Affiliated Hospital, Sun Yat-sen University, 10
- 11 Guangzhou, 510060, Guangdong, China

<sup>3</sup> Department of Gynecology, the First Affiliated Hospital, Sun Yat-sen University, 12 13 Guangzhou, 510060, Guangdong, China

- <sup>4</sup> Department of Nuclear Medicine, the First Affiliated Hospital, Sun Yat-sen University, 14
- 15 Guangzhou, 510060, Guangdong, China
- 16
- # authors contributed equally 17
- 18
- Correspondence: 19
- \*Yufeng Ren: renyuf@mail.sysu.edu.cn 20
- \*Guofen Yang: yangguof@mail.sysu.edu.cn 21
- 22

#### **Running title:** 23

Chemoresistance at the single cell level in ovarian cancer 24

#### 25 **Statement of significance**

We have identified key cells and core gene networks for early 26 chemoresistance in ovarian cancer. 27

28

#### **Conflict of Interest** 29

The authors declare no potential conflicts of interest. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30

#### 31 Abstract

Chemoresistance has long been a significant but unresolved issue in the treatment 32 of various cancers, including the most deadly gynecological cancer, the high-33 grade serous ovary cancer (HGSOC). In this study, single nuclei transcriptome 34 analyses were utilized to identify key cells and core networks for chemoresistance 35 in HGSOC patients with different early responses to platinum-based 36 chemotherapy at the single-cell level. Biomarkers for chemoresistance were also 37 screened using bulk transcriptome data from independent cohorts with larger 38 sample sizes. A total of 62,482 single cells from six samples were analyzed, 39 revealing that chemoresistant cancer cells (Epithelial cells 0) pre-existed within 40 individual patient before treatment. Two network modules formed with hub genes 41 such as hormone-related genes (ESR1 and AR), insulin-related genes (INSR and 42 IGF1R), and CTNNB1, were significantly overexpressed in these cells in the 43 chemoresistant patient. BMP1 and TPM2 could be promise biomarkers in 44 identifying chemoresistant patients before chemotherapy using 45 bulk transcriptome data. Additionally, chemotherapy-induced fibroblasts 46 (Fibroblasts 01 after) emerged as key stromal cells for chemoresistance. One 47 network module containing one subnetwork formed by cholesterol biosynthesis-48 related genes and one subnetwork formed by cancer-related genes such as STAT3 49 50 and MYC, was significantly overexpressed in these cells in the chemoresistant patient. Notably, the NAMPT-INSR was the most prioritized ligand-receptor pair 51 for cells interacting with Fibroblasts 01 after cells and Epithelial cells 0 cells to 52 drive the up-regulation of their core genes, including IL1R1, MYC and INSR 53 itself. Our findings deepen the understandings about mechanisms of early 54 chemoresistance in HGSOC patients. 55

56

#### 57 Key words:

chemoresistance, pre-existing cancer cells, induced fibroblasts, NAMPT-INSR,
ovarian cancer, single cell

#### 60 Introduction

Chemoresistance presents a formidable obstacle in the effective treatment 61 of various cancers, including the high-grade serous ovarian cancer (HGSOC), 62 which is the most lethal gynecologic malignancy (1). While initial responses to 63 chemotherapy are favorable for most patients (2), approximately one-third of 64 patients responding poorly to chemotherapy, with limited further treatment 65 options available (3). Furthermore, even patients initially responsive well to 66 chemotherapy may eventually develop chemoresistance, contributing to high 67 mortality rates in HGSOC (2). Despite decades of clinical application of 68 chemotherapy, the mechanism behind chemoresistance remains largely unknown. 69 Although individual chemoresistant targets have been identified using classical 70 biological experimental methods, their efficacy is usually limited due to the 71 inherent complexity of biological organisms. We thus need to analyze the 72 mechanism of chemoresistance at a higher resolution and at the systemic network 73 74 level.

75

Cell populations are fundamental to the execution of biological functions 76 77 in humans, and chemoresistance represents a selection process favoring cell populations with adaptive fitness phenotypes. A critical question arises: Do 78 79 different responses to chemotherapy pre-exist in patients before treatment, or are they acquired during treatment? Answering these questions necessitates a single-80 cell level analysis, including the differentiation of cancer cells with varying 81 chemotherapy responses and the interactions among cells in the tumor 82 microenvironments of patients with different responses. Previous studies in 83 different cancer types, such as breast cancer, rectal cancer, and oral squamous 84 cell carcinomas, have revealed diverse mechanisms of chemoresistance, with 85 either showing pre-existing genetic mutations for chemoresistance (4), or 86 demonstrating acquired transcriptional profile reprogramming during treatment 87 (5), or both (6). These findings underscore the need for specific analyses tailored 88

to each cancer type. One recent study has provided valuable insights into the
mechanisms of chemoresistance in HGSOC, but it focused on metastatic sites (7),
leaving the mechanisms at the primary sites of HGSOC relatively unclear.
Furthermore, the use of platinum-free intervals to characterize chemoresistance
remains controversial and may not directly reflect chemoresistance (8).

94

95 Therefore, in this study, we sought to investigate and compare cellular composition and corresponding transcriptional profiles at the primary sites before 96 97 and after platinum-based chemotherapy in patients with varying responses at the single-cell level. Our objectives were to address the following questions: Which 98 cell types are key cells for early chemoresistance? Are the corresponding gene 99 co-expression networks pre-existing or acquired? What are specific cellular 100 interactions in the microenvironments in chemoresistant patients? Our findings 101 will deepen our understandings about mechanisms of chemoresistance, and can 102 be helpful for finding potential biomarkers and therapeurtic targets for early 103 104 chemoresistant HGSOC patients.

105

#### 106 Materials and Methods

#### 107 Sampling and Library Construction

108 This study was approved by the Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University 109 (ethics approval No. 2021726). Six fresh paired primary HGSOC samples before 110 and after chemotherapy were collected from three patients who received 111 neoadjuvant chemotherapy (NACT) between 2021 and 2022 at the First 112 Affiliated Hospital, Sun Yat-sen University in Guangzhou, China. Clinical 113 information can be found in the Supplementary File 1. The chemotherapy 114 regimen consisted of three cycles of paclitaxel plus carboplatin. Paired samples 115 were obtained during laparoscopy and interval debulking surgery before and after 116 chemotherapy. Fresh tissues were immediately frozen in liquid nitrogen and 117

transported by dry ice. Single nuclei transcriptome libraries construction and 118 sequencing were conducted by Novogene (China) following 10x Genomics 119 instructions (https://support.10xgenomics.com). Briefly, libraries 120 were constructed using the Chromium Next GEM Chip G Single Cell Kit, 48 rxns (PN-121 100020), and Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead 122 Kit v3.1, 16 rxns PN-1000121. Libraries with PE150 (paired-end reads, 150bp) 123 124 were sequenced on an Illumina NovaSeq 6000.

125

#### 126 Chemotherapy Response Evaluation

All patients underwent baseline 18F-FDG PET/CT before and after 127 chemotherapy (Figure 1A). 18F-FDG PET/CT was performed after at least 6 128 hours of fasting and with a glucose level lower than 10 mmol/L. The PET/CT 129 scan coverage ranged from the top of the head to the mid-thigh. The ordered-130 subset expectation maximization iterative reconstruction method was used to 131 reconstruct the data. The total metabolic tumor volume (tMTV) and total lesion 132 glycolysis (TLG) were measured and calculated. Based on PERCIST 1.0 (9), we 133 differentiated patients as partial responses to chemotherapy (PR1 and PR2) and 134 135 progress disease (PD) (we named these IDs for this study and they were not used to identify patients outside the research group) (Figure 1B). 136

137

#### 138 Data Pre-processing

Raw data were analyzed with 10x Genomics Cell Ranger 6.1.1. The 139 GRCh38 Ensembl build genome (refdata-gex-GRCh38-2020-A) was used as the 140 reference. The filtered feature barcode matrix was used for further data analysis. 141 The Seurat v4 R package was used for data pre-processing (10). Only genes 142 expressed in at least three cells, and cells with at least 200 unique Molecular 143 Identifiers (UMI) were retained. Quality control metrics were plotted for 144 individual samples and used for filtering cells with aberrantly high UMI, which 145 could be originated from cell doublets or multiplets. The PercentageFeatureSet() 146

function was used to calculate the percentage of counts originating from mitochondrial DNA (mtDNA). Low-quality or dead cells with abnormal mitochondrial contamination were removed. Cell clusters with fewer than 10 cells were also removed. Cell cycle effects were evaluated with CellCycleScoring() function. Doublets were assessed using the DoubletFinder v2.0 R package (11).

153

Based on the plotting results (Supplementary File 2), quality control was 154 155 performed for each sample. For PR1 before (pre-chemotherapy sample of patient 1 with partial response to chemotherapy), cells with 200 < UMI < 7500, mtDNA 156 percentage < 8, ribosome percentage < 4 were retained, and 984 doublets were 157 removed. Similarly, for PR1 after (post-chemotherapy sample of patient 1 with 158 partial response to chemotherapy), cells with 200 < UMI < 5000, mtDNA 159 percentage < 2, ribosome percentage < 1 were retained, and 831 doublets were 160 removed. For PR2 before (pre-chemotherapy sample of patient 2 with partial 161 response to chemotherapy), cells with 200 < UMI < 7500, mtDNA counts < 6%, 162 ribosome percentage < 2 were retained, and 1057 doublets were removed. For 163 PR2 after (post-chemotherapy sample of patient 2 with partial response to 164 chemotherapy), cells with 200 < UMI < 4300, mtDNA percentage < 2.5%, 165 ribosome percentage < 2 were retained, and 1119 doublets were removed. For 166 PD before (pre-chemotherapy sample of the chemoresistant patient), cells with 167 200 < UMI < 6000, mtDNA percentage < 10, ribosome percentage < 2 were 168 retained, and 144 doublets were removed. For PD after (post-chemotherapy 169 sample of the chemoresistant patient), cells with 200 < UMI < 6000, mtDNA 170 percentage < 1, ribosome percentage < 2 were retained, and 367 doublets were 171 removed. 172

- 173
- 174 Data Integration, Clustering, and Differential Gene Expression Analysis

The preprocessed data were used for data integration analysis using Seurat 175 to correct batch effects among samples (10). 2000 highly variable expressed 176 genes detected for each sample were used to find anchors for data integration. 177 Subsequently, the integrated data was scaled, and the principal components were 178 computed. The top 30 principal components were identified using an elbow plot. 179 Clustering identification was performed at a proper resolution that can 180 181 differentiate major cell types. The UMAP dimensionality reduction was used for visualization. Differial expressed (DE) genes were identified with a significance 182 threshold of adjusted p value < 0.05 and log2FoldChange > 0.5. KEGG pathways 183 enrichment analyses were performed using the STRING database (https://string-184 db.org/) (12). 185

186

## 187 Malignant Cells Inference

Malignant cells were inferred based on genomic copy number variation 188 (CNV) using CopyKAT v1.1.0 (13). Cells with extensive genome-wide copy 189 190 number aberrations (aneuploidy) were considered as malignant tumor cells. ngene.chr=10, win.size=25. 191 Parameters set as KS.cut=0.1. were distance="euclidean". Only cells that met the criteria were presented. For the 192 PR2 after which contained only a small number of epithelial cells (15 cells), we 193 194 assumed that all these epithelial cells were malignant cells, since they all overexpressed malignance cell markers. 195

196

### 197 Gene Co-expression Network Construction

hdWGCNA (14) was used to construct high dimensional gene coexpression network modules for target cell clusters. Genes expressed in at least 5% of cells were used for analyses. Batch effects were corrected during analyses by setting group.by and group.by.vars parameters. The number of cells to be aggregated for metacells construction was 25, and the max\_shared was set as 10 as default. The TestSoftPowers was used to determine a proper value of the soft

power threshold. The implemented AddModuleScore function was applied to 204 compute hub genes signature scores for each module. Differential module 205 eigengene analysis was performed between target cell groups. Hub genes 206 overexpressed in the target cells in the network modules were further used to 207 construct protein-protein network using the STRING database (12). The 208 209 thickness of network edges represents the strength of data support. The minimum required interaction score was set as 0.7 (high confidence). Only genes with 210 interaction degrees >1 were presented. 211

212

213 Survival Analyses

Survival analyses were conducted using three publicly available bulk transcriptome datasets with clinical information, including GSE102073 (n=70), PRJNA866991 (n=41), and GSE32062 (n=260). Kaplan-Meier (K-M) survival curves were constructed using the survival 3.5 R package (15).

218

219 Bulk Transcriptome Analyses

For the GSE102073 cohort, the normalized gene expression matrix was 220 obtained directly from the GEO database. For the PRJNA866991 cohort, raw 221 reads were retrieved from the NCBI database and aligned to the GRCh38 222 223 Ensembl build human genome using HISAT2 v2.1.0 (16). SAMTOOLs v1.7 (17,18) was utilized to convert sam files to bam files, sort and index bam files, 224 and obtain the final counts. Featurecounts v2.0.4 (19) was used to obtain the 225 counts at the gene level. The DESeq2 v1.38.3 (20) was employed to normalize 226 the count files and generate the final expression matrix. For the GSE32062 cohort, 227 CEL files were first downloaded from the GEO database. The affy v1.74 R 228 package (21) was used to process the CEL files, and rma was applied for 229 230 normalization. The hgu133plus.db was used to extract the gene expression matrix at the gene level. 231

233 Cell-Cell Interaction Analyses

Nichenetr (22) was used to identify prioritized ligand-receptor-target genes
involved in the interactions from senders to receivers under different conditions.
All genes expressed in at least 10% of receiving cells were used as the
background geneset.

238

239 RNA Velocity Analyses

RNA velocity (the change in mRNA abundance calculated by relating the 240 abundance of unspliced and spliced mRNA) was estimated using Scvelo (23) 241 following the instructions (https://scvelo.readthedocs.io/en/stable/). 242 The stochastic model was chosen to account for stochasticity in gene expression, and 243 the combination of velocities across genes was used to estimate the future state 244 of individual cells. 245

246

247 Data Availability

All data produced in the present study are available upon reasonable request to the authors.

250


#### 251 **Results**

252 Cell atlas before and after chemotherapy in patients with different responses We collected six samples at primary ovary sites from three HGSOC 253 patients paired before and after chemotherapy. The responses to chemotherapy 254 were evaluated using PET/CT (Figure 1A and Figure 1B). The results of tMTV 255 and TLG of each patient before and after chemotherapy were given in Figure 1B. 256 Based on PERCIST 1.0 (9), we differentiated patients as partial responses to 257 chemotherapy (PR1 and PR2) and progress disease (PD). After quality control, a 258 total of 62482 single cells were grouped into nine major clusters, including 12668 259 epithelial cells (KRT19<sup>+</sup>), 41522 fibroblasts (DCN<sup>+</sup>), 1825 T cells (CD96<sup>+</sup>), 4850 260 Macrophages (CD163<sup>+</sup>), 1120 Endothelial cells (VWF<sup>+</sup>), 75 Lymphatic 261


endothelial cells (FLT4<sup>+</sup>), 213 B cells (MZB1<sup>+</sup>), 43 Schwann cells (LGI4<sup>+</sup>), and 262 166 Ciliated-secretory intermediate cells (CFAP54<sup>+</sup>FOXJ1<sup>+</sup>PAX8<sup>+</sup>) (24,25) 263 (Figure 1C). Malignant cells inference revealed that malignant cells were mainly 264 epithelial cells (Figure 1D), which is consistent with the pathological 265 characteristics of HGSOC as an epithelial cancer. A small portion of ciliated-266 secretory intermediate cells were also identified as malignant cells, which can be 267 268 explained since they were assumed to be the main origin of HGSOC (24,25). Expression profiles of corresponding markers in each cell type were provided in 269 270 Figure 1E. The cell numbers and ratios in each major cell cluster from individual patients were also presented in Figure 1F. The distribution of major cell clusters 271 in each sample among patients before and after chemotherapy were illustrated in 272 Figure 1G. 273


274


275



В







PR1

tMTV/cm3

652.97

43.03

TLG


1432.82

157.56

PET

before

after





PR2

	tMTV/cm3	TLG
before	449.84	1793.75
after	56.9	178.97

PET tMTV/cm3 TLG 178.59 before 56.18 after 87.82 305.91

PD





279 Figure 1 Schematic of sampling and analysis results. (A) Schematic of sampling. Fresh paired primary samples 280 before and after chemotherapy were collected from three patients who received neoadjuvant chemotherapy 281 (NACT). The chemotherapy regimen consisted of three cycles of paclitaxel plus carboplatin. PET/CT was used 282 to evaluate chemotherapy responses before and after chemotherapy for each patient. Paired samples were collected 283 during laparoscopy and interval debulking surgery before and after chemotherapy. Single nuclei transcriptome 284 libraries constructions were conducted following 10 x Genomics instructions. (B) Chemotherapy responses 285 evaluation. tMTV (total metabolic tumor volume) and TLG (total lesion glycolysis) were used to evaluate 286 chemotherapy responses. PR1 represents patient 1 with a partial response to chemotherapy, PR2 represents patient 287 2 with a partial response to chemotherapy, and PD represents progressive disease (chemoresistant patient). (C) 288 The UMAPT plot of cell atlas of integrated samples showing major cell clusters. (D) Malignant cells inference. 289 Aneuploid cells (malignant cells) and diploid cells (non-malignant cells) were identified. (E) The dot plot of 290 marker genes expression for each major cell cluster. (F) Cell numbers and cell ratios of each major cell cluster in 291 each individual sample. (G) The UMAP plot of cell atlas showing major cell clusters in each individual sample 292 among patients before and after chemotherapy. PD after represents the post-chemotherapy sample of the 293 chemoresistant patient, PD before represents the pre-chemotherapy sample of the chemoresistant patient, 294 PR1 after represents the post-chemotherapy sample of patient 1 with partial response to chemotherapy, 295 PR1\_before represents the pre-chemotherapy sample of patient 1 with partial response to chemotherapy, 296 PR2 after represents the post-chemotherapy sample of patient 2 with partial response to chemotherapy, and 297 PR2 before represents the pre-chemotherapy sample of patient 2 with partial response to chemotherapy.

298


#### 299 Chemoresistant cancer cells were pre-existing in the PD patient

300

Five subclusters of epithelial cells were identified in total (Figure 2A and 301 2B). No genes were specifically overexpressed in Epithelial cells 0, indicating 302 that this subcluster represented a common cancer cell type. Epithelial cells 1 303 specifically overexpressed MKI67 and enriched cell proliferation-related 304 305 pathways, such as homologous recombination, DNA replication, and the cell cycle. Epithelial cells 2 specifically overexpressed the hypoxia-related gene 306 307 PFKFB. Epithelial cells 3 specifically overexpressed DOCK8 and PTPRC, and 308 enriched immune response-related pathways, such as the B cell receptor and T cell receptor pathways. Epithelial cells 4, which only appeared in the partial 309 response after chemotherapy, specifically overexpressed DACH2 and OVGP1, 310 and enriched cancer-related pathways (Figure 2C, 2D). 311

Cell proportion analysis showed that Epithelial cells 0 cells were highly 313 enriched in the PD after, indicating its chemoresistant character (Figure 2E and 314 2F). DE genes retrieved from comparisons among samples after chemotherapy 315 for each subcluster also revealed that Epithelial cells 0 cells enriched many 316 cancer-related pathways in the PD after, such as the Wnt signaling pathway, the 317 MAPK signaling pathway, the insulin signaling pathway, the cellular senescence 318 319 pathway, and the longevity regulating pathway (Figure 2G). In contrast, although other subclusters also remained after chemotherapy in the PD after, their 320 321 proportions were largely reduced, and no cancer-related pathways were enriched, indicating their fragility to chemotherapy. Thus, we proposed that Epithelial 322 cells 0 cells were the key cancer cells for early chemotherapy responses. It is 323 worth noting that clustering analysis using cell average transcriptional profiles 324 clustered Epithelial cells 0 cells based on individual patient ID rather than 325 treatment condition (before or after chemotherapy) (Figure 2H), indicating that 326 transcriptional profiles for chemotherapy responses were largely pre-existing in 327 328 Epithelial cells 0 cells in individual patients before chemotherapy.





329

330 Figure 2 (A) The UMAP plot of cell atlas for five epithelial cells subclusters. (B) The UMAP plot of cell atlas 331 showing five epithelial cells subclusters in each individual sample among patients before and after chemotherapy. 332 PD after represents the post-chemotherapy sample of the chemoresistant patient, PD before represents the pre-333 chemotherapy sample of the chemoresistant patient, PR1 after represents the post-chemotherapy sample of 334 patient 1 with a partial response to chemotherapy, PR1 before represents the pre-chemotherapy sample of patient 335 1 with a partial response to chemotherapy, PR2 after represents the post-chemotherapy sample of patient 2 with 336 a partial response to chemotherapy, PR2 before represents the pre-chemotherapy sample of patient 2 with a partial 337 response to chemotherapy. (C) The dot plot of marker genes expression for epithelial cells subclusters. (D) KEGG 338 pathway enrichment for epithelial cells subclusters. (E) Cell numbers and cell ratios of cell subclusters in each 339 individual sample. (F) Cell ratio comparisons of the Epithelial cells 0 subcluster between samples before and 340 after chemotherapy in each patient. (G) KEGG pathway enrichment for the Epithelial cells 0 subcluster among 341 samples after chemotherapy. (H) Sample clustering using cell average transcriptional profiles clustered Epithelial 342 cells 0 cells based on individual patient ID rather than treatment condition (before or after chemotherapy).


343

344 Gene co-expression networks construction further supported the above results. We identified six co-expression modules for Epithelial cells 0 cells in 345 total. Module eigengene (ME) represents the first principal component of the 346 gene expression matrix comprising each module, and was thus used to summarize 347

the gene expression profile of the entire module. Figure 3A presented the 348 summarization of the expression of each module obtained by calculating gene 349 signature scores from MEs for the top 25 hub genes for each module. To correct 350 batch effects, harmony batch correction was applied to produce harmonized MEs 351 (hMEs) (Figure 3B). We can see that, again, pre- and post- chemotherapy 352 353 samples from the same patient expressed similar modules (Figure 3B). For 354 example, the PD patient overexpressed M3 and M4 modules both before and after chemotherapy. Differential module eigengene analysis revealed that no module 355 356 was significantly overexpressed in the post-chemotherapy sample when compared to the pre-chemotherapy sample from the same patient. For example, 357 although the adjust p value of M3 in the PD after was significant when compared 358 to PD before, its foldchange was small (Figure 3C left). Although the adjust p 359 values of M3 and M4 modules were significant in the PR1 after when compared 360 to the ones in the PR1 before, they actually expressed little in theses samples 361 (Figure 3C middle). This can be also applied to M4 and M6 modules in the PR2 362 patient (Figure 3C right). These results confirmed again that the transcriptional 363 profiles for different chemotherapy responses were pre-existing in cancer cells 364 365 before chemotherapy.

366

367 Notably, when comparing Epithelial cells 0 cells among samples after chemotherapy, M3 and M4 modules were significantly overexpressed in 368 Epithelial cells 0 cells in the PD after when compared to the ones in either 369 PR1 after or PR2 after (Figure 3D), indicating the chemoresistant characters of 370 these two modules. Further protein-protein co-expression networks using these 371 module genes overexpressed in the PD after showed that insulin-related 372 receptors (INSR and IGF1R), hormone receptor (AR), NCOR2, and SMAD2 373 374 formed a tight connective network in module M3, and a tight network with CTNNB1and ESR1 as the core hubs in module M4 (Figure 3E). 375




376

377 Figure 3 Gene co-expression networks construction and comparisons for Epithelial cells 0. (A) The UMAP plots 378 of the hub gene signature score for each module constructed for Epithelial cells 0. (B) Violin plots of the 379 harmonized module eigengenes (hMEs) in each sample for each module. (C) Differential module eigengene 380 comparisons between post- and pre-samples within each individual patient. (D) Differential module eigengene 381 comparisons between the PD after and the PR1 after or the PR2 after, respectively. (E) Co-expression networks 382 visualization of Module 3 and Module 4. PD after: post-chemotherapy sample of the chemoresistant patient. 383 PD before: pre-chemotherapy sample of the chemoresistant patient. PR1 after: post-chemotherapy sample of the 384 patient 1 with partial response to chemotherapy. PR1 before: pre-chemotherapy of the patient 1 with partial 385 response to chemotherapy. PR2 after: post-chemotherapy sample of the patient 2 with partial response to 386 chemotherapy. PR2 before: pre-chemotherapy of the patient 2 with partial response to chemotherapy. 387

The presence of pre-existing chemoresistance transcriptional profiles in cancer cells before chemotherapy lays the foundation for the search for relevant pre-treatment biomarkers. Survival analyses were thus conducted using publicly available bulk transcriptome data with progression-free survival (PFS) information, representing the time to first recurrence after chemotherapy. These analyses were performed using datasets from three independent cohorts: PRJNA866991 (n=41), GSE32062 (n=260), and GSE102073 (n=70). It is

important to note that these cohorts utilized bulk transcriptome data, where gene 395 expression represents the expression level of the entire sample rather than a 396 specific cell group. Additionally, these data were only retrieved from pre-397 chemotherapy conditions. We thus first identified DE genes that were 398 399 significantly overexpressed in the whole sample of PD before when compared to PR1 before and PR2 before. Subsequent survival analyses of these genes 400 revealed that only two genes, BMP1 and TPM2, were significantly associated 401 with low PFS across all three cohorts (Figure 4A). Both genes were also 402 significantly overexpressed in Epithelial cells 0 cells in the PD patient when 403 compared to samples of PR patients (Figure 4B). 404



405

406 Figure 4 (A) Kaplan-Meier survival curves on progression-free survival (PFS) for genes BMP1 and TPM2 from 407 three independent cohorts. (B) Violin plots showing gene expression patterns among samples at the sample level 408 before chemotherapy and at the Epithelial cells\_0 level after chemotherapy. (C) Sample clustering revealing that 409 the expression profiles of Ciliated-secretory intermediate cells were clustered based on individual patients rather 410 than treatment condition.

investigated chemoresistant genes in 412 We also ciliated-secretory intermediate cells since they were also remained in the PD after, and are assumed 413 to be the main origin of the high-grade serous ovarian carcinoma (HGSOC) 414 (24,25). Similar to Epithelial cells 0 cells, sample clustering also revealed that 415 the expression profiles of ciliated-secretory intermediate cells were clustered 416 417 based on individual patients rather than treatment condition (Figure 4C). There were only 17 genes overexpressed in Epithelial cells 0 cells when compared to 418 ciliated-secretory intermediate cells in the PD after with no pathways enriched, 419 indicating their similar transcriptional profiles. This indicated that ciliated-420 secretory intermediate cells in the PD after could also be chemoresistant, and the 421 corresponding transcriptional profiles were also pre-existing in individual 422 patients before treatment. 423

424

## 425 The induced fibroblasts after chemothrerapy are key cells for 426 chemoresistance

427

We initially identified four fibroblasts subclusters (Figure 5A). 428 429 Fibroblasts 0 occupied a large proportion in the tumor microenvironment after chemotherapy, indicating its association with chemotherapy. Notably, 430 431 Fibroblasts 0 was difficult to be clearly separated from Fibroblasts 1 in the UMAP plot with different resolutions, indicating that Fibroblasts 0 cells were 432 induced from Fibroblasts 1 during the treatment. Transcriptional dynamics 433 analysis also revealed that the transcriptional dynamics direction of Fibroblasts 1 434 before chemotherapy changed to the same direction of Fibroblasts 0 after 435 chemotherapy, except for a small portion of cells whose direction was more 436 inclined towards the pre-treatment direction. However, no DE gene was 437 specifically found to be overexpressed in this part. Additionally, when we 438 conducted sampling clustering using cellular average transcriptional profiles, we 439 found that unlike other subclusters, Fibroblasts 0 was always clustered together 440

with Fibroblasts\_1 in each sample (Figure 5B and 5C). We thus treated
Fibroblasts\_0 and Fibroblasts\_1 as one cluster named Fibroblasts\_01, and
differentiated pre-chemotherapy and post-chemotherapy clusters into
Fibroblasts\_01\_before and Fibroblasts\_01\_after (Figure 5D, Figure 5E and 5F).

All identified fibroblasts were epithelial-mesenchymal transition (EMT) 446 fibroblasts, as evidenced by their high expression of corresponding markers VIM, 447 ZEB1, and ZEB2 (Figure 5G). Although no genes were specifically 448 449 overexpressed in Fibroblasts 01 before, several genes were specifically overexpressed in Fibroblasts 01 after after chemotherapy. The top five 450 overexpressed DE genes for Fibroblasts 01 after in the PD after were SGCZ, 451 ACSM3, STAR, ESYT2, and INSR. Three pathways were enriched for this 452 subcluster, including ovarian steroidogenesis, longevity regulating pathway-453 multiple species, and FoxO signaling pathway. The corresponding genes were 454 IGF1R, INSR, STAR, FOXO1, and SGK1. Additionally, Fibroblasts 2 (FAP<sup>+</sup> 455 COL8A1<sup>+</sup> RUNX2<sup>+</sup>) specifically overexpressed FAP, COL8A1, and RUNX2, 456 and enrichment in pathways related to ovarian steroidogenesis, regulation of actin 457 cytoskeleton, AGE-RAGE signaling pathway in diabetic complications, and 458 amoebiasis. Fibroblasts 3 (MCAM<sup>+</sup>) specifically overexpressed MCAM and 459 enriched pathways such as pathways in cancer, cortisol synthesis and secretion, 460 vascular smooth muscle contraction, and cGMP-PKG signaling pathway (Figure 461 5H and 5I). 462

463

The sample clustering tree using average transcriptional profiles showed that all subclusters were clustered by treatment condition rather than patient IDs (Figure 5D), signifying that treatment condition played a critical role in fibroblasts among patients. When examining the enrichment of overexpressed genes in the PD\_after compared to PR1\_after and PR2\_after for each subcluster, only overexpressed genes in the Fibroblasts\_01\_after enriched many cancer-

- related signaling pathways, indicating that Fibroblasts\_01\_after in the PD\_after
  exhibited a high degree of malignancy (Figure 5J). Combined with the abundance
  after treatment for Fibroblasts\_01\_after (Figure 5A), we thus proposed that
- 473 Fibroblasts\_01\_after cells were the key cells for chemotherapy responses.









Figure 5 (A) The UMAP plot of cell atlas for fibroblasts subclusters with different resolutions. Left: the UMAP plot of cell atlas for fibroblasts subclusters in integrated samples. Middle: the UMAP plot of cell atlas for fibroblasts subclusters in each sample among patients before and after chemotherapy. Right: transcriptional dynamic depicted by RNA velocity for each subcluster. (B) Sampling clustering using cellular average transcriptional profiles for fibroblasts subclusters under resolution 0.12. (C) Sampling clustering using cellular average transcriptional profiles for fibroblasts subclusters under resolution 0.05. (D) Sampling clustering using cellular average transcriptional profiles for fibroblasts subclusters after treating Fibroblasts\_0 and Fibroblasts\_1

483 one subcluster. and differentiated pre-chemotherapy and post-chemotherapy clusters as into 484 Fibroblasts 01 before and Fibroblasts 01 after. (E) UMAP plot of fibroblast subclusters in integrated samples. 485 (F) UMAP plot of fibroblast subclusters in each sample from patients before and after chemotherapy. (G) Violin 486 plots depicting the expression of epithelial-mesenchymal transition (EMT) markers in each subcluster. (H) Dot 487 plot showing marker gene expression in fibroblast subclusters. (I) KEGG pathway enrichment analysis for 488 fibroblast subclusters. (J) KEGG pathway enrichment for overexpressed genes in the PD after for each subcluster. 489 PD after: Post-chemotherapy sample of the chemoresistant patient. PD before: Pre-chemotherapy sample of the 490 chemoresistant patient. PR1 after: Post-chemotherapy sample of patient 1 with partial response to chemotherapy. 491 PR1 before: Pre-chemotherapy sample of patient 1 with partial response to chemotherapy. PR2 after: Post-492 chemotherapy sample of patient 2 with partial response to chemotherapy. PR2 before: Pre-chemotherapy sample 493 of patient 2 with partial response to chemotherapy.

494

Gene co-expression networks construction revealed five network modules 495 496 for Fibroblasts 01 after cells in total (Figure 6A and 6B). The M2 module was significantly overexpressed in the PD after when compared to either PR1 after 497 498 or PR2 after, indicating its chemoresistance characters (Figure 6C). Proteinprotein network using hub genes of this module that overexpressed in the 499 PD after revealed two subnetworks. One was formed by many cholesterol 500 biosynthesis-related genes, such as HMGCR, SREBF2, MSMO1, MVD, ACAT2 501 and INSIG1. The other subnetwork was formed by well-known cancer promoting 502 genes such as MYC and STAT3 (Figure 6D), and enriched in many cancer-related 503 pathways such as HIF-1 signaling pathway, insulin resistance, JAK-STAT 504 signalling pathway, and type II diabetes mellitus. 505



506

Figure 6 Gene co-expression networks construction and comparisons for Fibroblasts\_01\_after. (A) The UMAP plots of the hub gene signature score of five modules constructed for Epithelial cells\_0. (B) Violin plots of the harmonized module eigengenes (hMEs) in each post-treatment sample for each module. (D) Differential module eigengene comparisons between PD\_after and PR1\_after or PR2\_after, respectively. (E) Co-expression network visualization using hub genes of Module 2. PD\_after: post-chemotherapy sample of the chemoresistant patient. PR1\_after: post-chemotherapy sample of the patient 1 with partial response to chemotherapy. PR2\_after: post-chemotherapy sample of the patient 2 with partial response to chemotherapy.

514

# 515Other stromal cells and immune cells in the microenvironment were516generally tumour-promoting among patients after chemotherapy

517

We identified four macrophage subclusters (Figure 7), including CD163<sup>+</sup> M2 macrophages (Macrophages\_0), hypoxic macrophages (Macrophages\_1) which overexpressed hypoxia-related genes (HK2<sup>+</sup>) (26), RRM2<sup>+</sup> M2 macrophages (Macrophages\_2), and fibrosis-like macrophages (Macrophages\_3) that overexpressed fibroblast-related genes (PDGFRA<sup>+</sup> and CALD1<sup>+</sup>), consistent with previous reports of macrophages being capable of transdifferentiating into


524 myofibroblasts (27). Following chemotherapy, a large proportion of 525 Macrophages\_0 cells and a few Macrophages\_1 cells remained in the PD\_after. 526 Only 31 genes were found to be overexpressed in the PD\_after compared to 527 PR1\_after and PR2\_after for Macrophages\_0, and no genes were overexpressed 528 in the PD\_after for Macrophages\_1.

529

530 Furthermore, we identified five T cell subclusters (Figure 7), including CD8<sup>+</sup>THEMIS<sup>+</sup> T cells [21,22] (T cells 0), natural killer (NK) cells 531  $(NCAM1^+CD3^-)$  (28) (T cells 1),  $CD4^+$  regulatory T cells 532 (Tregs)  $(CD4^+CTLA4^+FOXP3^+IL2RA^+)$  (29) (T cells 2), TOP2A<sup>+</sup> T cells (30) (T 533 cells 3), and MEG3<sup>+</sup> T cells (31–33) (T cells 4). The  $CD8^+$  THEMIS<sup>+</sup> T cells 534 represented a large proportion after treatment. Only 14 genes were found to be 535 overexpressed in the PD\_after compared to PR1\_after and PR2\_after, and no 536 specific pathway enrichment was observed. A small proportion of NKT-like cells 537 remained in the PR1 after and the PD after, with no DE genes identified between 538 539 them. These results indicated a generally similar immunosuppressive microenvironment after chemotherapy among patients. 540

541

Regarding Lymphatic endothelial cells (Figure 1), only four genes were 542 overexpressed in the PD after, including RMST, STAT3, NAMPT, and YBX3. 543 For Schwann cells (Figure 1), no DE genes were identified among patients after 544 treatment. Similarly, for Endothelial cells (Figure 1), only 47 DE genes were 545 found to be overexpressed in the PD after compared to PR1 after and PR2 after, 546 such as NAMPT, SEMA3A, RMST, and ATP1B3, and no significantly enriched 547 pathways were observed. These results indicated that these stromal cells 548 exhibited generally similar characteristics after chemotherapy among patients. 549



550

551 Figure 7 (A) Left: UMAP plot of macrophage subclusters for integrated samples. Middle: UMAP plot of 552 macrophage subclusters for each sample among patients before and after chemotherapy. Right: Dot plot of marker 553 gene expression in each macrophage subcluster. (B) Left: UMAP plot of T cell subclusters for integrated samples. 554 Middle: UMAP plot of T cell subclusters for each sample among patients before and after chemotherapy. Right: 555 Dot plot of marker gene expression in each T cell subcluster. PD after: Post-chemotherapy sample of the 556 chemoresistant patient. PD before: Pre-chemotherapy sample of the chemoresistant patient. PR1 after: Post-557 chemotherapy sample of patient 1 with partial response to chemotherapy. PR1 before: Pre-chemotherapy sample 558 of patient 1 with partial response to chemotherapy. PR2 after: Post-chemotherapy sample of patient 2 with partial 559 response to chemotherapy. PR2\_before: Pre-chemotherapy sample of patient 2 with partial response to 560 chemotherapy.

561

## The NAMPT-INSR was the most prioritized ligand-receptor pair enriched in the chemoresistance patient

564

565 Cell-cell interactions play crucial roles in executing cellular functions. 566 Since Epithelia cells\_0 cells and Fibroblasts\_01\_after cells were key cells for 567 chemoresistance, we thus would like to see which cells interacted with them and


affected their core genes expression. The genes that were significantly overexpressed in Epithelial cells\_0 cells in the PD\_after in M3 and M4 modules we identified above were used as the target geneset when Epithelial cells\_0 cells were as the receivers. Similarly, the genes that were significantly overexpressed in Fibroblasts\_01\_after cells in the PD\_after in M2 module we identified above were used as the target genesets when Fibroblasts\_01\_after cells were as the receivers.

575

576 Interestingly, results consistently showed that the NAMPT-INSR was the most prioritized ligand-receptor pair for cells interacting with Epithelial cells 0 577 cells (receiver cells) in the PD after when compared to PR1 after and PR2 after. 578 For example, INSR was the most potentially interacted receptor for NAMPT for 579 Fibroblasts 01 after cells (sender) interacting with Epithelial cells 0 cells 580 (receiver) in the PD after compared to PR1 after (Figure 8A left) and PR2 after 581 (Figure 8B left). NAMPT was the only ligand with high ranking for ligand 582 583 activity, and also with high expression level in Fibroblasts 01 after in the PD after compared to PR1 after (Figure 8A right) and PR2 after (Figure8B 584 585 right). The corresponding downstream target genes were IL1R and INSR in the PD after compared to PR1 (Figure 8A right) and PR2 (Figure 8B right). These 586 587 results were also applied to other cells interacting with Epithelial cells 0 cells in the PD after to drive the overexpression of IL1R and INSR as the downstream 588 genes, such as Endothelial cells, Fibroblasts 2, Fibroblasts 3, Lymphatic 589 endothelial cells, and T cells 0, which were given in the Supplementary File 3. 590

591

The NAMPT-INSR was also the most prioritized ligand-receptor pair for cells interacting with Fibroblasts\_01\_after cells (receiver) in the PD\_after when compared to PR1\_after and PR2\_after, with MYC and INSR itself as the downstream target genes, such as Fibroblasts\_3 and Lymphatic endothelial cells (Figure 8C and 8D, Supplementary File 3).



598

599 Figure 8 Cell-cell interactions analyses. (A) Ligand-receptor inference (left) and target genes inference (right) 600 when Fibroblasts\_01\_after cells acted as senders and interacted with Epithelial\_cells\_0 cells as receivers in the 601 PD after compared to PR1 after. The NAMPT-INSR was the most prioritized ligand receptor pair, with IL1R 602 and INSR itself as the downstream target genes. (B) Ligand-receptor inference (left) and target genes inference 603 (right) when Fibroblasts\_01\_after cells acted as senders and interacted with Epithelial\_cells\_0 cells as receivers

604 in the PD after compared to PR2 after. The NAMPT-INSR was the most prioritized ligand receptor pair, with 605 IL1R and INSR itself as the downstream target genes. (C) Ligand-receptor inference (left) and target genes 606 inference (right) when Fibroblasts\_3 cells acted as senders and interacted with Fibroblasts\_01\_after cells as 607 receivers in the PD after compared to PR1 after. The NAMPT-INSR was the most prioritized ligand receptor 608 pair, with MYC and INSR itself as the downstream target genes. (D) Ligand-receptor inference (left) and target 609 genes inference (right) when Fibroblasts 3 cells acted as senders and interacted with Fibroblasts 01 after cells 610 as receivers in the PD after compared to PR2 after. The NAMPT-INSR was the most prioritized ligand receptor 611 pair, with MYC and INSR itself as the downstream target genes. PD\_after: Post-chemotherapy sample of the 612 chemoresistant patient. PR1 after: Post-chemotherapy sample of patient 1 with partial response to chemotherapy. 613 PR2 after: Post-chemotherapy sample of patient 2 with partial response to chemotherapy.

614

#### 615 **Discussion**

In this study, we revealed that chemoresistant cancer cells were pre-616 617 existing in individual patients prior to treatment. This observation aligns with existing research that cancer cells are often clustered by patient IDs, highlighting 618 the strong individual differences among cancer cells (34,35), which can 619 contribute to the heterogeneity of tumors in individual patients. These results 620 provide a foundation for developing biomarkers to diagnose chemoresistance 621 622 before initiating treatment. We identified BMP1 and TPM2 as promising universal candidate biomarkers for identifying chemoresistant patients before 623 624 treatment when using bulk transcriptome data. Both genes can facilitate chemoresistance (36,37), supporting the rationality of our analyses. 625

626

We found two co-expression network modules were significantly 627 overexpressed in Epithelial cells 0 cells in the chemoresistant sample. One 628 network was formed with hub genes such as ESR1 and CTNNB1. The other 629 module network was formed by tight connections among genes of IGF1R and 630 INSR, AR, NCOR2 and SMAD2. CTNNB1 has been suggested as a potential 631 biomarker for chemoresistance in breast cancer (38), which can be a good 632 candidate therapeutic target for chemoresistance in HGSOC. Notably, two 633 hormone-related genes, ESR1 and AR, were involved in these core networks. 634 Hormone imbalance can contribute to the development of ovarian cancer, and 635

both androgen and estrogen have been reported to regulate proliferation and 636 progression in ovarian cancer (39,40). Our findings here thus highlight the critical 637 roles of these hormones in chemoresistance in HGSOC which deserve 638 consideration. Additionally, two hub genes are insulin receptors (IGF1R and 639 INSR). The enrichment of insulin resistance pathway in Epithelial cells 0 cells 640 in the chemoresistant sample further supports the potential link between insulin 641 642 and early chemoresistance. Insulin is well-known for cellular metabolism and growth (41). It is known that chemotherapy-induced insulin resistance can impair 643 anti-cancer efficacy (42). Elevated circulating insulin due to insulin resistance, 644 coupled with overexpressed insulin receptors in cancer cells can confer a 645 selective advantage to promote proliferation and migration (43,44), and thus 646 contributing to chemoresistance in HGSOC. Our findings thus underscore the 647 importance of insulin-related genes in early chemoresistance in HGSOC. 648

649

In addition to cancer cells, other cells in the tumor microenvironment can 650 651 also play crucial roles in chemotherapy responses. Unlike the pre-existing cancer cells, our findings indicated that the induced fibroblasts (Fibroblasts 01 after) 652 following chemotherapy were key cells associated with chemoresistance. A 653 subnetwork formed by cholesterol biosynthesis-related genes was found in the 654 module that was significantly overexpressed in Fibroblasts 01 after cells in the 655 chemoresistant sample. Cholesterol biosynthesis can support cancer progression 656 and also induce drug resistance (45). For example, gene SREBF2 has been 657 reported to facilitate chemoresistance in ovarian cancer (46). Our results thus 658 implies the importance of cholesterol metabolism in chemoresistance in HGSOC. 659 Another subnetwork was formed by cancer-related genes such as STAT3 and 660 MYC. The overexpression of both genes have well been linked to 661 chemoresistance in ovarian cancer (47,48). Genes within these subnetworks 662 could have critical roles in chemoresistance and are good candidate targets. 663

664

Cellular interactions in the tumor microenvironment are vital for 665 chemoresistance. Our analysis revealed that the NAMPT-INSR was the most 666 prioritized ligand-receptor pair enriched in the chemoresistant sample when cells 667 interacting with the two key cell types, i.e. Epithelial cells 0 and 668 Fibroblasts 01 after. NAMPT as a rate-limiting enzyme for NAD synthesis, is 669 required for cellular metabolism and DNA repair, for example, as the substrate 670 of PARPs (a DNA repair enzyme whose inhibitors are widely used in second-line 671 therapy for HGSOC) (49). Recent studies have highlighted the potential function 672 of NAMPT as an alternative ligand for INSR (50), which can enhance insulin 673 resistance (51), which can impair anti-cancer efficacy as we mentioned above. 674 Besides, similar to insulin, NAMPT can stimulate glucose uptake and 675 proliferation through INSR to confer a selective advantage to promote 676 proliferation and migration of cancer cells as we mentioned above. Moreover, 677 NAMPT treatment can induce fibrosis by overproducing profibrotic molecules 678 through the INSR transduction pathway (51). This can contribute to 679 680 chemoresistance by creating a physical barrier to protect from chemotherapeutic drugs (52). All these findings gave strong supports for the involvement of 681 NAMPT-INSR in chemoresistance in HGSOC patients. We further identified that 682 IL1R1, MYC and INSR were the downstream target genes of NAMPT-INSR. 683 MYC and INSR can induced chemoresistance as we mentioned above. The 684 chemoresistant functions of these target genes gave further support that NAMPT-685 INSR can have critical roles in chemoresistance in HGSOC patients, although the 686 specific mechnism involved in HGSOC needs further investigation. 687

688

Notably, NAMPT was overexpressed in Fibroblasts\_01\_after cells only after chemotherapy. This aligns with previous findings about the overexpression of NAMPT at the onset of drug resistance (53). NAMPT can be induced by hypoxia via a STAT3-dependent mechanism (54). Additionally, MYC can interact with the NAMPT promoter and stimulate its expression to promote

cancer (55,56). The overexpression of both STAT3 and MYC in the PD\_after in
Fibroblasts\_01\_after cells in our study can help explain the overexpression of
NAMPT in these cells after chemotherapy. Our cellular interactions analyses
showed that MYC was also the downstream target gene of NAMPT in
Fibroblasts\_01\_after in the PD\_after. Indeed, MYC and NAMPT are involved in
a positive feedback loop to drive tumorigenesis (56). The consistent results
supported the reliability of our analyses.

701

702 The immune microenvironment in patients with varying chemotherapy responses exhibited a general trend of being inhibited and proinflammatory after 703 chemotherapy. The proportions of T cells, both before and after chemotherapy. 704 were observed to be small, which aligns with the characteristic of ovarian cancer 705 being a "cold" tumor (57). Notably, Ciliated-secretory intermediate cells 706 displayed a close transcriptional profile with Epithelial cells 0 cells in the 707 PD after, consistent with the hypothesis that they are the primary origin of 708 709 HGSOC, originating from the fallopian tube and fall off to the ovary (24,25). Although other stromal cells showed minimal differences in gene expression 710 among samples after chemotherapy, the majority of them exhibited 711 overexpression of NAMPT in the chemoresistant patient. This is in line with the 712 findings that the NAMPT-INSR pair was highly enriched when these stromal 713 cells interacted with Fibroblasts 01 after cells and Epithelial cells 0 cells in the 714 chemoresistant patient (Supplementary File 3). 715

716

### 717 Conclusions

In conclusion, we found that pre-existing cancer cells and induced fibroblasts as key contributors for early chemoresistance in HGSOC patients. Metabolism reprogramming, involving hormone-related genes (ESR1 and AR), insulin-related genes (IGF1R and INSR) and cholesterol biosynthesis-related genes, could play critical roles in early chemoresistant HGSOC. CTNNB1,

STAT3 and MYC as core hub genes are also good candidate chemoresistant
targets. The NAMPT-INSR ligand-receptor pair enriched for cells interacted with
Fibroblasts\_01\_after cells and Epithelial cells\_0 cells, can be important for early
chemoresistance in HGSOC.

727

We thus propose that the combination of chemotherapy with INSR 728 729 inhibitors and NAMPT inhibitors could represent a promising treatment strategy for early chemoresistant HGSOC patients. The inhibitors of NAMPT and INSR 730 731 have undergone extensive development and clinical testing (58,59). Previous research has demonstrated that the combination of a NAMPT inhibitor and 732 chemotherapy resulted in a better prognosis than chemotherapy alone in mice 733 with HGSOC (60), holds promise for further improving the therapeutic window. 734 Despite the limitations in sample size, our study has yielded valuable clinic 735 findings, enrich the heterogeneous library of HGSOC and could offer important 736 insights into potential clinical biomarkers and therapeutic targets for HGSOC 737 chemoresistance. The findings from our study may also contribute to 738 advancements in understanding and addressing chemoresistance in various 739 740 cancer types in a broad sense.

741

#### 742 Acknowledgments

We thank the valuable suggestions from Yunfei Zhao and Prof. Canwei
Xia. We also would like to acknowledge the computer support provided by Prof.
Yang Liu, Yuqing Han, and Ximin He.

746

#### 747 Funding

This study was supported by the National Key R&D Program of China (2022YFC2704200), the National Natural Science Foundation of China (81903037), the Natural Science Foundation of Guangdong Province, China (2020A1515011281), and the Nature Science Foundation of China

(No.81772769). Part of the data computation was supported by NationalSupercomputer Center in Guangzhou, China.

754

## 755 Authors contributions

Langyu Gu and Guofen Yang proposed the study. Langyu Gu conducted 756 the single nuclei transcriptome data analyses. Shasha He and Yu Zeng conducted 757 chemotherapy responses evaluation. Linxiang Wu proposed the sampling plan 758 and provided the clinical information. Guofen Yang, Hongwei Shen, and 759 Linxiang Wu conducted the sampling. Langvu Gu, Yang Zhang, Chuling Wu, 760 and Huishan Xu conducted survival analyses. Langyu Gu, Chenging Zheng, and 761 Xiaovan Zhang conducted pathways enrichment analyses. Guofen Yang, Yufeng 762 Ren, Shasha He, and Shuzhong Yao provided funding supports. Langvu Gu wrote 763 the manuscript, with all authors providing comments and approval. 764

765

### 766 **References**

- Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck
   A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr
   Canc Netw. 2019;17:896–909.
- Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet (London, England). 2014;384:1376–88.
- Gonzalez Bosquet J, Newtson AM, Chung RK, Thiel KW, Ginader T, Goodheart MJ, et
   al. Prediction of chemo-response in serous ovarian cancer. Mol Cancer. 2016;15:66.
- Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance
  Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell.
  2018;173:879–93.e13.
- Qin P, Chen H, Wang Y, Huang L, Huang K, Xiao G, et al. Cancer-associated fibroblasts
  undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell
  and spatial transcriptomics. Cell Rep Med. 2023;4:101231.
- 6. Sharma A, Cao EY, Kumar V, Zhang X, Leong HS, Wong AML, et al. Longitudinal
  single-cell RNA sequencing of patient-derived primary cells reveals drug-induced
  infidelity in stem cell hierarchy. Nat Commun. 2018;9:4931.
- 783
  7. Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, et al. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Sci Adv. 2022;8:eabm1831.
- 8. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 2018;150.
- Joo Hyun O, Lodge MA, Wahl RL. Practical percist: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280.

- 791 10. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated 792 analysis of multimodal single-cell data. Cell. 2021;184:3573-87.
- 793 McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-11. 794 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Sys. 2019;8:329-795 37.
- 796 Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The 12. 797 STRING database in 2023: protein-protein association networks and functional 798 enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 799 2023;51:D638-46.
- 800 13. Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, et al. Delineating copy number 801 and clonal substructure in human tumors from single-cell transcriptomes. Nat 802 Biotechnol. 2021;39:599-608.
- 803 14. Morabito S, Reese F, Rahimzadeh N, Miyoshi E, Swarup V. hdWGCNA identifies co-804 expression networks in high-dimensional transcriptomics data. Cell Reports Methods. 805 2023; 3:100498.
- 806 15. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer, 807 New York; 2000.
- Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and 808 16. 809 genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907-15.
- 810 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence 17. 811 Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078-9.
- 812 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence 18. 813 Alignment / Map (SAM) Format and SAMtools 1000 Genome Project Data Processing 814 Subgroup. Bioinformatics. 2009; 25:2078-9.
- 815 19. Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for 816 assigning sequence reads to genomic features. Bioinformatics. 2014;30:923-930.
- 817 20. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 818 RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
- 819 21. Gautier L, Cope L, Bolstad BM, Irizarry RA, Affy - Analysis of Affymetrix GeneChip 820 data at the probe level. Bioinformatics. 2004;20:307-315.
- 821 Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by 22. 822 linking ligands to target genes. Nat Methods. 2020;17:159-62.
- Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to 823 23. 824 transient cell states through dynamical modeling. Nat Biotechnol. 2020;38:1408–14.
- 825 Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al. The Repertoire of 24. 826 Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing 827 of Normal Fallopian Tube Epithelial Cells. Cancer Cell. 2020;37:226-42.
- 828 25. Dinh HQ, Lin X, Abbasi F, Nameki R, Haro M, Olingy CE, et al. Single-cell 829 transcriptomics identifies gene expression networks driving differentiation and 830 tumorigenesis in the human fallopian tube. Cell Rep. 2021;35:108978.
- 831 26. Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A, Sica A. Hypoxia-mediated regulation of macrophage functions in pathophysiology. Int Immunol. 2013;25:67–75. 832
- 833 27. Tang PC-T, Chung JY-F, Xue VW-W, Xiao J, Meng X-M, Huang X-R, et al. Smad3 834 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast 835 Transition. Adv Sci. 2022;9:e2101235.
- 836 Väyrynen JP, Haruki K, Lau MC, Väyrynen SA, Ugai T, Akimoto N, et al. Spatial 28. Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker 837 838 Analysis of the Colorectal Cancer Microenvironment. Cancer Immunol Res 839 2022;10:215-27.
- Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T 840 29.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.03.24302058; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

841 Cells and Human Disease. Annu Rev Immunol. 2020;38:541–66.

- 842 30. Li Y, Wang Z, Han F, Zhang M, Yang T, Chen M, et al. Single-cell transcriptome
  843 analysis profiles cellular and molecular alterations in submandibular gland and blood in
  844 IgG4-related disease. Ann Rheum Dis. 2023;82:1348–58.
- Li J-Q, Hu S-Y, Wang Z-Y, Lin J, Jian S, Dong Y-C, et al. Long non-coding RNA
  MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of
  Treg/Th17 in immune thrombocytopenic purpura. Biomed Pharmacother. 2016;83:905–
  11.
- Qiu Y-Y, Wu Y, Lin M-J, Bian T, Xiao Y-L, Qin C. LncRNA-MEG3 functions as a competing endogenous RNA to regulate Treg/Th17 balance in patients with asthma by targeting microRNA-17/ RORγt. Biomed Pharmacother. 2019;111:386–94.
- Wang J, Liu X, Hao C, Lu Y, Duan X, Liang R, et al. MEG3 modulates TIGIT
  expression and CD4 + T cell activation through absorbing miR-23a. Mol Cell Biochem.
  2019;454:67-76.
- Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor
  heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat
  Commun. 202112:2540.
- Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, et al. A single-cell landscape
  of high-grade serous ovarian cancer. Nat Med. 2020;26:1271–9.
- 36. Zhang J, Zhang J, Xu S, Zhang X, Wang P, Wu H, et al. Hypoxia-Induced TPM2
  Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.
  Cell Physiol Biochem. 2018;45:692–705.
- 37. Xie F, Zhang D, Qian X, Wei H, Zhou L, Ding C, et al. Analysis of cancer-promoting
  genes related to chemotherapy resistance in esophageal squamous cell carcinoma. Ann
  Transl Med. 2022;10:92.
- 866 38. Ozcan G. PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to
  867 neoadjuvant chemotherapy in ER+/HER2- breast cancer. Front Oncol.
  868 2023;13:1216438.
- 869 39. Chung WM, Chen L, Chang WC, Su SY, Hung YC, Ma WL. Androgen/androgen
  870 receptor signaling in ovarian cancer: Molecular regulation and therapeutic potentials.
  871 Int. J. Mol. Sci. 2021; 22:7748.
- Rothenberger NJ, Somasundaram A, Stabile LP. The role of the estrogen pathway in the
  tumor microenvironment. Int. J. Mol. Sci. 2018; 19:611.
- 41. Le TKC, Dao XD, Nguyen DV, Luu DH, Bui TMH, Le TH, et al. Insulin signaling and
  its application. Front. Endocrinol. (Lausanne). 2023; 14:1226655.
- 42. Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EGE, Jalving M. Cancer-drug
  induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev.
  2015;41:376–84.
- 43. Vigneri R, Sciacca L, Vigneri P. Rethinking the Relationship between Insulin and Cancer. Trends Endocrinol Metab. 2020;31:551–60.
- 44. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer.
  2011;18:R125-47.
- 45. Huang B, Song B liang, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2020; 2:132-141.
- 46. Zheng L, Li L, Lu Y, Jiang F, Yang X-A. SREBP2 contributes to cisplatin resistance in ovarian cancer cells. Exp Biol Med (Maywood). 2018;243:655–62.
- 47. Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
  889 Oncogene. 2019;38:564–80.
- 890 48. Gong K, Dong Y, Wang L, Duan Y, Yu J, Sun Y, et al. Nanoparticle overcomes

medRxiv preprint doi: https://doi.org/10.1101/2024.02.03.24302058; this version posted February 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

sphingosine-1-phosphate receptor-1-mediated chemoresistance through inhibiting
s1pr1/ p-stat3 axis in ovarian carcinoma. Int J Nanomedicine. 2020; 15:5561-5571.

- 49. Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, et al.
  Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
  Oncotarget. 2016;7:2968–84.
- 896 50. Peng Q, Jia SH, Parodo J, Ai Y, Marshall JC. Pre-B cell colony enhancing factor induces
  897 Nampt-dependent translocation of the insulin receptor out of lipid microdomains in
  898 A549 lung epithelial cells. Am J Physiol Endocrinol Metab. 2015;308:E324–33.
- Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295:F1485–94.
- 52. Tajaldini M, Poorkhani A, Amiriani T, Amiriani A, Javid H, Aref P, et al. Strategy of
  targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling
  new era to cancer chemo-immunotherapy resistance. Eur J Pharmacol.
  2023;957:175991.
- Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide
  Phosphoribosyltransferase in Malignancy: A Review. Genes and Cancer. 2013; 4:44756.
- 54. Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide
  phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 2010;3:522–7.
- 911 55. Wei Y, Xiang H, Zhang W. Review of various NAMPT inhibitors for the treatment of
  912 cancer. Front Pharmacol. 2022;13:970553.
- 56. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The cMYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1
  deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012;109:E187–
  96.
- 917 57. Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and
  918 future perspectives. Clin Immunol. 2021;226:108707.
- 58. Tang H, Wang L, Wang T, Yang J, Zheng S, Tong J, et al. Recent advances of targeting
  nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery. Eur J
  Med Chem. 2023;258:115607.
- 59. Zhang X, Zhu X, Bi X, Huang J, Zhou L. The Insulin Receptor: An Important Target
  for the Development of Novel Medicines and Pesticides. Int J Mol Sci. 2022; 23:7793.
- 60. Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, et al.
  NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with TherapyInduced Senescence in Ovarian Cancer. Cancer Res. 2020;80:890–900.